Co-Diagnostics (NASDAQ:CODX) was upgraded by analysts at Maxim Group to a "hold" rating.
Co-Diagnostics (NASDAQ:CODX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $1.50 price target on the stock.
Co-Diagnostics (NASDAQ:CODX) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health
Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA